Succipro

Innovation in Drug Development

Succipro is a spin-off from the Pere i Virgili Health Research Institute (IISPV) and the Rovira i Virgili University, dedicated to creating innovative pharmaceutical solutions for the treatment of inflammatory and metabolic diseases. They work to transform pioneering scientific discoveries into therapies that improve the quality of life for patients.

First-in-class

Succipro stands out for its first-in-class therapies (i.e., the first in their category), leading innovation in drug development to address unmet medical needs. Their research focuses on:

Succinic Acid as a therapeutic target: A pioneering strategy for the treatment of metabolic diseases.
Personalized therapy: The application of biomarkers to design treatments tailored to the specific needs of each patient.
Safety and efficiency: A commitment to creating drugs that minimize adverse effects, always prioritizing patient safety.

Innovation and Science

We focus on cutting-edge biotechnology research for the treatment of inflammatory bowel diseases and other associated disorders. Our technology originates from the diabetes and related metabolic diseases research group at IISPV. Our current project primarily focuses on a drug for inflammatory bowel disease, which is in the preclinical phase with promising results. This drug uses a mechanism of action based on succinate modulation, aiming to provide a more efficient, safe, and less invasive therapeutic solution than current options.

Follow us!

Mission

Leverage unique and excellent scientific knowledge about succinate biology to develop new therapeutic agents that reduce excessive succinate levels, promote a healthy microbiome, reduce intestinal and systemic inflammation, and prevent fibrosis. SUCCIPRO plans to advance its main program toward early-stage clinical development for Inflammatory Bowel Disease (IBD), as well as explore additional indications for the technology in other diseases presenting elevated succinate levels, such as fatty liver associated with metabolic dysfunction.

Vision

Succinate modulation therapies will provide new, safe, and effective therapeutic alternatives for patients suffering from chronic diseases with a strong chronic inflammatory component, creating a significant positive impact on health and long-term quality of life for the general population.

Public funds

Project 101114086 funded by the WomenTechEU program
(call HORIZON-EIE-2022-SCALEUP-02; Topic HORIZON-EIE-2022-SCALEUP-02-02; Action type HORIZON-CSA)

The company has received funding from the StartUp Capital Program, with the support of ACCIO (code ACE052/22/000049)

PTQ2022-012572 funded by MCIN/AEI /10.13039/501100011033
PTQ2023-012978 funded by MCIN/AEI /10.13039/501100011033
PTQ2024-013834 funded by MCIN/AEI /10.13039/501100011033

Title: SUCCIPRO SL Business Plan: New *first-in-class* succinate-modulating therapies for the treatment of inflammatory and metabolic disorders. Project framed within the NEOTEC 2023 program, funded by CDTI, supported by the Ministry of Science and Innovation, and co-financed by the European Union – Next Generation EU, for the preclinical development of innovative, safe, and monitorable *first-in-class* drugs capable of modulating succinate.

Execution: 01/10/2023–31/03/2025.

Amount: €335,000.

File Number: SNEO-20231359.

Project CPP2024-011364, funded by the Ministry of Science, Innovation and Universities, the State Research Agency, and the ERDF (MICIU/ AEI / 10.13039/501100011033 / ERDF, EU).

Funding from the International Intercompany Program (CIIP-20252009, “Development of a Novel First-in-Class Biologic Succinate Modulation Therapy for Crohn’s Disease”, with co-financing from CDTI and the European Union’s Horizon Europe Research and Innovation Framework Programme)